Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or Death

Loading news article.

Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or Death | WAPE

Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or Death

Article summary

Related companies

Comments —